Subscriber login:
Remember me
CLINICAL & FORMULARY MANAGEMENT STRATEGY
Review Formulary Management Considerations for Opportunities and Strategies and P&T Committee Planning Support
Access Published Guidelines, Health Outcomes, Pharmacoeconomics, and Clinical Trials
Anticipate Market Shifts, Pipeline Events, Manufacturer
Life-Cycle Management Strategies, and
Financial Implications
Understand Key Clinical, Cost, Utilization, Reimbursement, and Market-Competition Factors
IPD's Payer & Provider Insights combine advanced pharmaceutical landscape market visibility with a team of Executive Clinical Pharmacists to provide comprehensive pharmacy and therapeutic management strategy, supporting formulary, clinical, contracting, and market-access decisions.
Our subscribers gain around-the-clock access to IPD's proprietary web platform, real-time alerts, comprehensive reports, new drug reviews, podcast episodes, and expert consultations.
-
In-depth analysis regarding drug availability, clinical data, clinical pipeline tracking, evidence-based clinical pathways, preferred products, and site of care
-
Disease class-specific strategy reports, drug alerts, pipeline trend reports, and new-drug reviews
-
Assessments of potential new brand product prevalence and pricing impacts prior to launch
-
Extensive trend analysis examining brand vs. generic clinical pathways, cost-effective therapies, and payer perspectives
-
Pricing specific to competitive landscape including generic-launch projections, FDA action dates, sales, therapy costs, and price changes
-
Trend reports highlighting disease classes and drug events important to payers, systems, and manufacturers throughout the country
-
Clinical criteria, formulary coverage, step therapy, and limited distribution network tracking
Explore Recent Reports
January 2026
Drug Pipeline and Trend Report 1H 2026
IPD Analytics has released its “Drug Pipeline and Trend Impact Report: 1H 2026,” highlighting 41 high-impact drugs across various therapeutic areas that are nearing potential approval by the FDA over the next 12 months. For each of the drugs analyzed, IPD has provided an assessment of the clinical efficacy, expected place in therapy, approval outlook, estimated cost, and anticipated reimbursement and distribution channel.
December 2025
Novel Drugs in the Oncology Pipeline 1H 2026
IPD Analytics has released its report “Novel Drugs in the Oncology Pipeline for 1H 2026,” providing an overview of new molecular entities (NMEs) and novel biologics expected to receive FDA approval through NDAs or BLAs in early 2026. The report assesses how these emerging therapies may influence oncology treatment pathways, payer coverage strategies, and potential budget impact, with most agents anticipated to be administered in the outpatient setting.